NCBiotech News

Precision BioSciences, a Durham-based genome editing company, has formed a strategic collaboration potentially worth more than $445 million with global biopharmaceutical company Gilead Sciences, to develop new therapies aimed at curing hepatitis B infections.

With ongoing rain and flooding from Hurricane Florence, NCBiotech is making the following changes to operating hours today, Monday September 17.

• Eastern office (Greenville) closed
• Greater Charlotte office closed
• Piedmont Triad office (Winston-Salem) closed
• Southeastern office (Wilmington) closed

Many of these office teams are working off-site, conditions permitting. You can likely reach them via email. Our RTP and Western (Asheville) offices are open regular hours. 

 

Raleigh-based UVision360 has achieved a dual-indication clearance from the U.S. Food and Drug Administration for its all-in-one LUMINELLE DTx Hysteroscopy System to be used clinically for hysteroscopy and cystoscopy in women.

Durham-based Mycovia Pharmaceuticals, formerly Viamet Pharmaceuticals, has begun two Phase 3 clinical trials of its lead drug candidate for treating recurrent yeast infections in women.

North Carolina Central University will soon make it easier for area biopharmaceutical companies to fill job vacancies with qualified employees via online courses offered through NCCU’s Biomanufacturing Research Institute and Technology Enterprise (BRITE).

Grifols, a global biotherapeutics company with major operations in North Carolina, has received approval from the U.S. Food and Drug Administration for a new formulation of GamaSTAN, its medicine for treating patients who’ve been exposed to the hepatitis A or measles viruses.

A novel drug candidate aimed at preventing and treating hereditary angioedema (HAE) – a recurrent and severe swelling disorder – has shown positive results in a clinical trial, according to its Durham-based developer, BioCryst

Research Triangle Park-based CertriRx recently started doing business as Verinetics. But the young company hasn’t changed its focus, or the speed with which it is making inroads in anti-counterfeiting technology.

Ken Hoffman, a veteran of the clinical diagnostics industry, was living and working in Boston some 20 years ago when he chose to move his new startup company, Cygnus Technologies, to the small North Carolina coastal community of Southport to enjoy a different lifestyle. It led to big-time success and growth.

As the co-founder, CEO and board chair of Javara Inc., a privately funded Winston-Salem clinical research services firm, Jennifer Byrne is convinced her company’s newly minted “Integrated Research Organization" platform offers a more-effective solution to the immense challenges of patient enrollment in clinical trials.

As algae blooms fed by chemical fertilizer runoff from farms and lawns contaminate more waterways every year, Mirimichi Green Express is rooting its future in high-end eco-sensitive plant-growing products in the Southeastern North Carolina community of Castle Hayne, near Wilmington.

Durham-based 410 Medical, developer of a new medical device for treating critically ill patients, has raised $3.1 million in new financing to commercialize the product.

A simple idea became a life-changing one for a young Duke physician assistant who never planned to do anything but practice medicine. Now Shawn Gage is not only an inventor, but an entrepreneur too.

Aerie Pharmaceuticals, an ophthalmic pharmaceutical company based in Durham, has reported positive clinical results for Rhopressa, its once-daily eye drop approved for the reduction of elevated eye pressure, a cause of glaucoma.

Hernan Navarro, Ph.D., retired chief scientist for RTI International’s Center for Drug Discovery, has returned to the workplace to direct the Biomedical Research Institute and Technology Enterprise (BRITE) at North Carolina Central University in Durham.